T-CELL PROLYMPHOCYTIC LEUKEMIA
Clinical trials for T-CELL PROLYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new T-CELL PROLYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for T-CELL PROLYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail targets Hard-to-Treat leukemia
Disease control Recruiting nowThis early-phase trial tests whether combining three drugs—ruxolitinib, cladribine, and venetoclax—can control T-cell prolymphocytic leukemia (T-PLL) that has returned or not responded to prior treatment. The study will enroll 36 adults and primarily monitor safety and side effec…
Matched conditions: T-CELL PROLYMPHOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Cord blood cells engineered to fight Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new treatment using immune cells (NK cells) from donated cord blood that are engineered to target a protein called CD5 found on certain cancer cells. The treatment is given after chemotherapy to prepare the body, and the goal is to see if it is safe and effecti…
Matched conditions: T-CELL PROLYMPHOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Experimental drug combo aims to tackle tough lymphoma
Disease control Recruiting nowThis trial investigates whether combining two FDA-approved drugs, duvelisib and venetoclax, can safely and effectively treat peripheral T-cell lymphoma that has returned or stopped responding to prior therapies. The study enrolls adults who have tried at least two previous treatm…
Matched conditions: T-CELL PROLYMPHOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New hope for tough blood cancers: LP-118 trial launches
Disease control Recruiting nowThis early-stage study tests a new oral drug, LP-118, in up to 100 adults with blood cancers like lymphoma, leukemia, or myeloma that returned or didn't respond to prior therapy. The main goals are to find the safest dose and see if the drug can shrink tumors or slow the disease.…
Matched conditions: T-CELL PROLYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug may keep T-Cell lymphoma at bay after transplant
Disease control Recruiting nowThis phase II trial is testing whether the drug ruxolitinib, taken as a daily pill after a stem cell transplant, can help prevent T-cell lymphoma from coming back and reduce the risk of graft-versus-host disease (GVHD). The study will enroll 44 adults with various T-cell lymphoma…
Matched conditions: T-CELL PROLYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Jonathan Brammer • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug cocktail aims to tame rare blood cancers
Disease control Recruiting nowThis early-phase trial tests two drugs, ruxolitinib and duvelisib, together in people whose T- or NK-cell lymphoma has come back or stopped responding to treatment. The main goal is to find the safest dose of duvelisib when combined with a fixed dose of ruxolitinib. About 70 part…
Matched conditions: T-CELL PROLYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Scientists dig into rare blood cancer to unlock better care
Knowledge-focused Recruiting nowThis study gathers information from 50 people with T-cell prolymphocytic leukemia (T-PLL), a rare and aggressive blood cancer. Researchers will look at patients' medical records, lab results, and genetic data to better understand the disease and how it responds to current treatme…
Matched conditions: T-CELL PROLYMPHOCYTIC LEUKEMIA
Sponsor: French Innovative Leukemia Organisation • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Massive T-Cell lymphoma database aims to unlock new insights
Knowledge-focused Recruiting nowThis study is creating a large database of information and tissue samples from 1,000 people with T-cell lymphoma. Researchers will use this data to learn more about the disease and how to improve patient outcomes. Participants provide medical information and optional blood and na…
Matched conditions: T-CELL PROLYMPHOCYTIC LEUKEMIA
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC